Lori Hilden

Lori Hilden is currently the Senior Director at Eli Lilly and Company, specializing in crystallization, physical characterization, particle engineering, and polymorphism. They have held various roles within the company since 2014, after serving as a Senior Research Scientist from 2007 to 2014 and as a Research Investigator at Bristol-Myers Squibb from 2002 to 2007. Lori co-owns HM Investment Properties, a position they have held since 2005. They completed their Doctor of Philosophy (Ph.D.) in Pharmaceutics at Purdue University from 1998 to 2001, where they also conducted research as a Graduate Student Researcher until 2002.